Anzeige
Mehr »
Dienstag, 21.04.2026 - Börsentäglich über 12.000 News
BREAKING: Pacifica liefert hochgradige Treffer - Phase II trifft genau ins Ziel
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2QCUH | ISIN: SE0014855029 | Ticker-Symbol: 8IM1
Tradegate
20.04.26 | 16:30
4,205 Euro
+1,45 % +0,060
Branche
Gesundheitswesen
Aktienmarkt
Sonstige
1-Jahres-Chart
IMPLANTICA AG SDR Chart 1 Jahr
5-Tage-Chart
IMPLANTICA AG SDR 5-Tage-Chart
RealtimeGeldBriefZeit
4,3554,55512:03
4,4204,53512:03

Aktuelle News zur IMPLANTICA Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08:42Implantica announces landmark RefluxStop study of 602 patients across 22 European centers, with up to 6.75-year follow-up, published in Nature's Scientific Reports237VADUZ, Liechtenstein, April 21, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop...
► Artikel lesen
26.03.Implantica publishes Year-end Report, January - December 2025 (Q4)261VADUZ, Liechtenstein, March 26, 2026 /PRNewswire/ -- RefluxStop US Launch Coming Closer, pending FDA approvalSignificant events in the fourth quarter FDA completed six pre-approval...
► Artikel lesen
IMPLANTICA Aktie jetzt für 0€ handeln
25.02.Implantica AG: Implantica publishes Year-end Report, January - December 2025 (Q4)269RefluxStop® US Launch Coming Closer, pending FDA approval Significant events in the fourth quarter FDA completed six pre-approval inspections during the quarter - including manufacturing sites,...
► Artikel lesen
18.02.Implantica presents the Year-end Report (Q4 2025) on February 25 at 15:00 CET310VADUZ, Liechtenstein, Feb. 18, 2026 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the Year-end Report (Q5 2025) at 15:00 CET on February 25. The Year-end Report...
► Artikel lesen
27.01.Implantica announces major public tender wins in Italy securing over EUR 1.2 million funding for RefluxStop417VADUZ, Liechtenstein, Jan. 27, 2026 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device...
► Artikel lesen
10.12.25Implantica strengthens market expansion as Italy's leading Careggi University Hospital in Florence introduces RefluxStop468VADUZ, Liechtenstein, Dec. 10, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique device...
► Artikel lesen
25.11.25Implantica: RefluxStop 'Best in Class' at Japan Foregut Conference as 5-Year Data and Extensive Safety Cohort is Presented to 120 Leading Surgeons371VADUZ, Liechtenstein, Nov. 25, 2025 /PRNewswire/ -- Implantica AG (publ), a medtech company at the forefront of introducing advanced technology into the body, announced today that its innovative...
► Artikel lesen
25.11.25IMPLANTICA: RefluxStop "Best in Class" at Japan Foregut Conference as 5-Year Data and Extensive Safety Cohort is Presented to 120 Leading Surgeons8
11.11.25Implantica: RefluxStop takes center stage at 2025 European Foregut Society meeting473VADUZ, Liechtenstein, Nov. 11, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the unique...
► Artikel lesen
31.10.25Implantica publishes Interim Report January - September 2025 (Q3)401VADUZ, Liechtenstein, Oct. 31, 2025 /PRNewswire/ -- RefluxStop® Nears FDA Approval - Strong Momentum Toward US Market Entry Significant events in the...
► Artikel lesen
27.10.25Implantica presents the third quarter 2025 on October 31 at 15:00 CET336VADUZ, Liechtenstein, Oct. 27, 2025 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the third quarter 2025 at 15:00 CET on October 31. The interim report...
► Artikel lesen
13.10.25Implantica completes FDA 100-Day Meeting for RefluxStop PMA application446VADUZ, Liechtenstein, Oct. 13, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative...
► Artikel lesen
06.10.25Implantica Successfully Completes MDSAP Recertification Audit382VADUZ, Liechtenstein, Oct. 6, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative...
► Artikel lesen
25.09.25Implantica steps up to close the treatment gap with RefluxStop as main device competitor exits Europe and the UK550VADUZ, Liechtenstein, Sept. 25, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device...
► Artikel lesen
24.09.25Implantica announces U.S. FDA has provided feedback on the final RefluxStop PMA submission, Module 3458VADUZ, Liechtenstein, Sept. 24, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including a unique device...
► Artikel lesen
17.09.25Implantica's RefluxStop sparks strong excitement at the American Foregut Society meeting, ahead of pending US FDA approval468VADUZ, Liechtenstein, Sept. 17, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop®...
► Artikel lesen
10.09.25Implantica ramps-up production with 10,000 RefluxStop units in preparation for U.S. launch, pending FDA PMA approval438VADUZ, Liechtenstein, Sept. 10, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop®...
► Artikel lesen
14.08.25Implantica publishes Interim Report January - June 2025 (Q2)516VADUZ, Liechtenstein, Aug. 14, 2025 /PRNewswire/ -- Transforming Clinical Excellence of RefluxStop® into Strategic Market Momentum Significant events in the second quarter of 2025 FDA...
► Artikel lesen
13.08.25Implantica finishes new multi-cavity production tool for RefluxStop to support manufacturing ramp-up in the U.S. pending FDA approval450VADUZ, Liechtenstein, Aug. 13, 2025 /PRNewswire/ -- Implantica AG (publ.), a medtech company at the forefront of introducing advanced technology into the body, including the innovative RefluxStop®...
► Artikel lesen
07.08.25Implantica presents the second quarter 2025 on August 14 at 15:00 CEST374VADUZ, Liechtenstein, Aug. 7, 2025 /PRNewswire/ -- Implantica AG (publ) invites investors to a presentation of the second quarter 2025 at 15:00 CEST on August 14. The interim report for the...
► Artikel lesen
Weiter >>
33 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1